Revance Therapeutics (Nasdaq: RVNC) 40.3% HIGHER; announced positive 24-week results today from its multi-center BELMONT Phase 2 active comparator study ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Special Reports

NXP Semiconductors (NXPI) Hit by Late 3Q Demand Weakness; Susquehanna Cuts Price Target to $100 October 29, 2015 3:21 PM Decline in Secure Interfaces and Power Business Hits NXP Semiconductors' (NXPI) Revenue; Needham & Company Cuts Price Target to $100 October 29, 2015 3:14 PM NXP Semiconductors (NXPI) Guides 4Q Down vs. Flat Consensus; Mizuho Securities Reiterates Buy October 29, 2015 2:00 PM Amgen (AMGN) Sees Double-Digit EPS Growth Out to 2018; UBS Raises Price target to $180 October 29, 2015 10:46 AM Allergen (AGN)/Pfizer (PFE) Deal Creates Mid-Teens Synergies in Year 2 - RBC CapitalOctober 29, 2015 10:40 AM Poor New Product Sales Negatively Effect GoPro's (GPRO) 3Q Revenue; Northland Capital Markets Cuts Price Target to $39 October 29, 2015 10:38 AM Alliance Fiber Optic Products' (AFOP) Top Customer Cuts Spending; Needham & Company Cuts Price Target to $20 October 29, 2015 9:54 AM